Latest Implications of Next-Gen Sequencing in Diagnosis of Acute and Chronic Myeloid Leukemia by Boldura, Oana Maria et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Latest Implications of Next-Gen 
Sequencing in Diagnosis of Acute 
and Chronic Myeloid Leukemia
Oana Maria Boldura, Cristina Petrine, Alin Mihu  
and Cornel Balta
Abstract
The spectacular progress which was present in the past few years in the field 
of genome sequencing, together with the appearance on the market of some high 
performance devices in this field, the reduction of the costs regarding the analysis 
of the samples and the standardization of some protocols, has led to the establish-
ment and introduction of the new generation of sequencing techniques in clinical 
diagnostic labs. An important role is played by the implementation of this technique 
in the oncology clinics. In this context, we found it appropriate to discuss in this 
chapter about the role of next-gen sequencing in determining the genetic probabili-
ties of occurrence of oncological pathologies in the healthy population, the screen-
ing of these diseases at the population level, the diagnosis and classification of this 
pathology, the establishment of the therapeutic conduct using the technique, as well 
as the progression of the disease. In this chapter, we intend to discuss in particular 
the involvement of this technology in hemato-oncological diseases.
Keywords: next-generation sequencing, acute myeloid leukemia, chronic myeloid 
leukemia, molecular diagnosis
1. Introduction
The rapid development of the new sequencing techniques, the development 
of databases for the analysis and comparison of the various pathologies, as well 
as the reduction of the costs related to their exploitation and the total value of the 
cost related to the analysis, will lead to the implementation of this technique in the 
clinical diagnostic laboratories. Also the implementation of this technique leads to 
the need to develop and comply with standards, which will result in the develop-
ment of valid and useful results to the clinician. This technique is used especially for 
the diagnosis and monitorization of hereditary diseases, being able to evaluate the 
genetic changes that appeared in both germline and somatic cell lines, focusing on 
evaluating mutations occurring at the level of a single gene, evaluating gene panels 
involved in the molecular pathobiology of various disorders, as well as the evalua-
tion of the various protein-coding genes involved in this process [1]. In view of the 
above, we can conclude that this technique brings important information to the cli-
nician, both about the presence of a possible mutation which will cause an affection, 
as well as about the metabolic interactions and the play of gene expression involved 
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in the pathobiological mechanism of diseases, thus offering not only an early and 
accurate diagnosis but also the possibility of highlighting molecular targets for 
therapy, as well as a precise assessment of the progression of the disorders, being 
necessary correlated with standardized clinical and paraclinical examinations.
The Food and Drug Administration (FDA) has prepared and finalized a docu-
ment guiding the use of next-generation sequencing in germline disease assess-
ment, which was published on April 12, 2018, under the name of “Considerations 
for Design, Development and Analytical Validation of Next Generation Sequencing 
(NGS) - In Vitro Based Diagnostics (IVDs) Intended to Aid in the Diagnosis of 
Suspected Germline Diseases,” thereby trying to take a step forward to standardize 
and introduce this technique into the current practice of diagnostic laboratories, but 
at the same time making sure that the patient’s safety is the number one priority in 
front of technological innovations and possible analytical errors [2].
Lately, the progress in this field has had as a direct consequence on the drastic 
decrease of the cost with this analysis, at the same time developing over 55,000 
genetic tests for more than 11,000 pathological conditions.
Remarkable results could be noticed after the implementation of this technology 
in the diagnosis and follow-up of the progression of oncological pathologies, among 
them being noted Hodgkin’s lymphoma, breast cancer, and chronic myelogenous 
leukemia. Also this technique brings real benefits in the diagnosis, understand-
ing, and study of the progression of cardiovascular diseases in direct correlation 
with the therapy administered to digestive, respiratory, and nervous disorders. 
Particular importance must also be given to the power of this new technology to aid 
microbiological diagnosis, as well as its usefulness in establishing the resistance of 
pathogenic microorganisms to various anti-infectious agents.
2. Acute myeloid leukemia: patho-molecular mechanism and diagnosis
The introduction of the new generation sequencing techniques has led to the 
development of knowledge of the mechanisms that govern the gene mechanisms 
that trigger and lead to the progression of malignant oncological diseases of the 
myeloid line. Besides the chromosomal mutations revealed by classical cytogenetic 
methods, observed on a larger scale, the next-generation sequencing revealed 
numerous other genetic alterations, which could not be revealed using classical 
methods. These studies have revealed some genetic similarities in various mor-
phologically distinct conditions, suggesting that they have a similar molecular 
mechanism, these mechanisms being represented by cell signaling, transcription, 
regulation of the cell cycle, regulation of DNA methylation, changes occurred in 
histone regulation, RNA splicing, and alterations of the components of the sister 
chromatid cohesion complex [3]. All these genetic alterations can represent a start-
ing point in the development of molecular biomarkers, which can be easily moni-
tored by the new sequencing techniques; in Figure 1, the complex genetic substrate, 
involved in the induction and evolution of the malignant pathologies of the myeloid 
line is presented, hence being instrumental in establishing the diagnosis, prognosis, 
and therapeutic option, some of them being already validated and used in current 
practice.
Acute myeloid leukemia is part of the myeloid hemato-oncological disorders 
with high aggression, which affects the blood cells, being the leukemia with the 
highest weight in the adult population, having an unfavorable prognosis, despite the 
spectacular progression of the new therapies applied to this pathology, which leads 
to the in-depth study and a better understanding of the molecular processes that 
occur during the evolution of the disease.
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An important first step in understanding the molecular and genetic mechanisms 
that governed the occurrence and progression of AML was the introduction of 
chromosome analysis by banding; this analysis provides relationships on the chro-
mosome level changes, with direct resonance in the molecular pattern modification 
and clinically being specific for the disease. The first genetic alteration discovered 
and correlated with the evolution of promyelocytic leukemia was the translocation 
of t (15;17), but in the progression of this pathology, other chromosomal alterations 
appear, such as the translocation of t (8;21), inversion of 16, all of which are associ-
ated with a favorable prognosis, while the association of these alterations together 
with the existence of structural alterations will lead to the establishment of an 
unfavorable prognosis.
Mutations affecting the cell lines involved in AML can be classified into two 
main categories: Class I mutations leading to the promotion of monoclonal cell 
proliferation and Class II mutations leading to the inhibition of myeloid differentia-
tion into mature, immunocompetent cell stages; this classification is illustrated in 
Figure 2 [4].
Highlighting these mutations will lead to the diagnosis of most acute myeloid 
leukemias with normal cytogenetic profile. In this context, the new generation 
sequencing is a useful element in the discovery of leukemias with normal cytoge-
netic profile, being able to discover even new mutations involved in the progression 
of this pathology. Also in the pathogenesis of these diseases, not only the DNA 
substrate modifications are involved, represented by the gene mutations or chro-
mosomal translocations, but also epigenetic mechanisms that dictate the expression 
Figure 1. 
Metabolic pathways affected in the oncological malignant pathology of the myeloid lineage that could be used as 
potential biomarkers in the diagnosis of these disorders [3].
Biochemical Analysis Tools - Methods of Bio-molecules studies
4
of these genes, such as the changes produced at the histone level and DNA methyla-
tion, may also be implicated. There are also miRNAs that can act as oncogenes or as 
tumor suppressor genes [5, 6]. Thus, the combination of new generation sequenc-
ing techniques, functional genomics and proteomics, will contribute to a better 
understanding, highlighting new therapeutic targets and new treatment modalities 
for AML in the future.
The alterations produced in the genetic material of the myeloid cell lines 
involved in the appearance of AML, lead directly to both functional and numerical 
alterations of these cells, as well as to structural and morphological alterations, 
alterations that are important in the primary hematological diagnosis, highlighted 
by smears made from peripheral blood samples or samples from the hematogenous 
spinal cord (Figure 3).
Figure 2. 
Molecular models of mechanism involved in acute myeloid leukemia [4].
Figure 3. 
Peripheral blood samples from a patient with AML, May Grunwald Giemsa stain (MGG), magnification 
stage 1000X. Picture (A) contains a myeloblast next to a dysplastic agranular hypersegmented neutrophil and 
picture (B) shows a myeloblast surrounding RBC that shows discrete anisochromia, slight anisocytosis, and a 
polychromatophilic RBC on the bottom right.
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Myeloblasts are described as intermediate sized cells, ranging from 14 to 18 μm 
(when compared to a neutrophil that has the size between 10 and 15 μm) with a 
nucleo-cytoplasmatic ratio largely in favor of the nucleus (ranging from 4/1 to 
5/1 in favor of the nucleus) containing a large, mostly oval-shaped nucleus contain-
ing very fine nonagreggated chromatin in which 2 or more nucleoli can usually be 
seen; the cytoplasm is strongly basophilic and may contain Auer rods [7, 8].
Auer rods are rod-shaped crystalline structures that are derived from primary 
granules of the myeloid cells. They are mainly reported in AML. They were first 
reported by John Auer in 1906 and, interestingly, were considered to be inclu-
sions inside lymphoblasts. In the current day, they are considered of diagnostic 
importance to indicate both the linage and the neoplastic nature of the condition 
observed [7, 8] (Figure 4).
The European Leukemia Network recommends genetic testing of people 
diagnosed with acute myeloid leukemia, in order to have a complete picture of 
the risk initiation for each patient, thus being able to use the most appropriate 
strategy in the fight with this disease. The main genetic markers that can be used 
are: t (8;21) (q22; q22.1)/RUNX1-RUNX1T1, t (15;17)/PML-RARA, t (9;11) (p21.3; 
q23.3)/MLLT3-KMT2A, other types of translocation may occur that affect KMT2A 
genes, t (6;9) (p23; q34.1)/DEK-NUP214, inv (3) (q21.3; q26.2) or t (3;3) (q21.3; 
q26.2)/GATA2, inv (16) (p13.1q22) and/or t (16;16) (p13.1; q22)/CBFB-MYH11, 
MECOM, chromosome loss 5/5q, 7, or 17/17p, mutations in CEPBA (biallelic), 
NPM1, RUNX1, ASXL1 and TP53, and internal tandem duplications (ITD) in the 
FLT3 gene [9–11].
The most common Next-Gen Sequencing platform currently on the market are 
offered by Illumina (San Diego, CA, USA), being represented by iSeq100, miniSeq, 
miSeq, nextSeq System, HiSeq2500, HiSeqX Ten, and NovaSeq, and Thermo Fisher 
Scientific (Waltham, MA, USA) offers the Ion Proton System, Ion PGM System, Ion 
S5 System, Ion S5 XL System, Ion GeneStudio S5 System, and the HID GeneStudio 
S5 System.
For myeloid disease, various NGS Gene panels were designed and validated. 
Those panels are represented by the proposal of:
a. SureSeq myPanel™ NGS Custom AML (Oxford Gene Technology, Begbroke, 
Oxfordshire, UK);
Figure 4. 
Bone marrow aspirate from a patient with AML: in picture (A), on the right middle part, a myeloblast 
displaying a Auer rod surrounded by multiple myeloblasts is shown, and in picture (B), a dysplastic oxyphilic 
erythroblast showing nuclear abnormalities(multiple nuclei, some being incompletely divided) along with 
myeloblasts (MGG X 1000) is shown.
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b. Leuko-Vantage Myeloid Neoplasm Mutation Panel (Quest Diagnostics, 
Madison, NJ, USA);
c. AmpliSeq® Myeloid Sequencing Panel (Illumina); and
d. Human Myeloid Neoplasms Panel (Qiagen, Venlo, the Netherlands).
A comparison between these panels is described succinctly by Matynia et al. [12] 
in Table 1.
From this panel, it is recommended to choose the genes to be analyzed according 
to the choice of the diagnostician. This panel also includes RNA markers for fusion 
driver genes and expression genes that are not completely listed. The genes listed 
here come from three other panels and represent combinations between the genes 
listed. The Web source of this panel presents no other information about the hotspot 
or the complete gene [13, 14].
The use of NGS techniques can detect mutations in the pretreatment phase, 
thus having utility in assessing the risk of these patients, establishing the prognosis, 
making an appropriate and personalized therapeutic decision for each patient, and 
may even lead to changes in the classification of these types of diseases by WHO.
3.  Chronic myeloid leukemia: patho-molecular mechanism and 
diagnosis
Chronic myeloid leukemia is a hemato-oncologic disease, in which a monoclonal 
line proliferates. The cells are derived from the hematopoietic stem cell, being 
characterized by aberrant expression of the BCR/ABL oncogene, arising from the 
chromosomal translocation t (9;12) (q34; q11). This mutation leads to disruption 
of the fusion protein, increasing the activity of tyrosine kinase, which will lead to 
proliferation out of control of the myeloid line [15].
This pathology represents about 15–20% of the cases of leukemia in adults, the 
main clinical features being represented by leukocytosis, the deviation to the left of 
the leukocyte formula, with splenomegaly, having an progression in three phases: 
the initial chronic phase, which can last several years, manifested by increasing the 
number of myeloid cells, but will retain their differentiation capacity and func-
tions, most patients being asymptomatic. The second phase is an intermediate 
step of acceleration that can last from several months to several years, difficult to 
diagnose, being most often discovered following routine blood checks, which high-
light the increase in the number of immature and frequent blood cells associated 
symptoms. In the final blastic phase, immature blood cells predominate, and the 
hope of survival is several months. In this phase, the genetic instability increases, 
accumulating these defects, and together with them will increase the resistance to 
drug therapy (Figure 5) [16].
The first line in the diagnosis of CML, right after the cell blood count (CBC) 
done by an automated analyzer, is the blood smear.
Morphology of the peripheral blood smear plays a crucial role in CML due to the 
differential diagnosis. A well-done blood smear could exclude a leukemoid reaction 
(in CML, basophilia is found) and can fastly assess the severity of the disease (high 
basophil count could be a clue that the disease is heading toward an accelerated 
phase that, eventually, turns into acute leukemia) as well as a blast crisis (blasts 
more than 20% that shows the change into acute leukemia) [17].
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Qiagen Human Myeloid Neoplasms Panel
ASXL1 (full) NPM1 (full) CBL (full) SETBP1 (full) GATA2 (full)
CEBPA (full) NRAS (full) CSF3R (full) SF3B1 (full) HRAS (full)
DNMT3A (full) RUNX1 (full) ETV6 (full) SRSF2 (full) IKZF1 (full)
FLT3 (full) TET2 (full) EZH2 (full) ZRSR2 (full) KMD6A (full)
IDH1 (full) TP53 (full) GATA1 (full) ABL1 (full) MYC (full)
IDH2 (full) U2AF1 (full) JAK2 (full) BRAF (full) MYD88 (full)
KIT (full) WT1 (full) MPL (full) CREBBP (full) NF1 (full)
KMT2A (full) BCOR (full) PHF6 (full) DDX41 (full) NTRK3 (full)
KRAS (full) CALR (full) PTPN11 (full) EGFR (full) PDGFRA (full)
PRPF8 (full) RB1 (full) SH2B3 (full) SMC1A (full) STAG2 (full)
Total 50 genes available
Illumina AmpliSeq Myeloid Panel
ASXL1 (full) NRAS (hotspot) — ZRSR2 (full) MYC 
(expression)
CEBPA (full) RUNX1 (full) EZH2 (full) ABL1 (hotspot) MYD88 (hotspot)
DNMT3A (hotspot) TET2 (full) — BRAF (hotspot) NF1 (full)
FLT3 (hotspot) TP53 (full) JAK2 (hotspot) CREBBP (fusion) NTRK3 (fusion)
IDH1 (hotspot) U2AF1 (hotspot) MPL (hotspot) — PDGFRA 
(fusion)
IDH2 (hotspot) WT1 (hotspot) PHF6 (full) EGFR (fusion) PRPF8 (full)
KIT (hotspot) BCOR (full) PTPN11 
(hotspot)
GATA2 (hotspot) RB1 (full)
KMT2A (fusion) CALR (full) SETBP1 
(hotspot)
HRAS (hotspot) SH2B3 (full)




NPM1 (hotspot) CSF3R (hotspot) SRSF2 
(hotspot)
— STAG2 (full)
Total 46 genes available
Quest Diagnostics LeukoVantage Panel
ASXL1 NRAS — ZRSR2 —
CEBPA RUNX1 EZH2 — —
DNMT3A TET2 GATA1 — —
FLT3 TP53 JAK2 — —
IDH1 U2AF1 MPL DDX41 —
IDH2 WT1 — — —
KIT — PTPN11 — —
KMT2A CALR SETBP1 — —
KRAS CBL SF3B1 — —
NPM1 CSF3R SRSF2 KMD6A —
Total 30 genes available
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The bone marrow aspirates in CML are hypercellular with an expansion of the 
granulocytes (e.g., neutrophils, eosinophils, and basophils) and their progenitor 
Figure 5. 
Evolution of chronic myeloid leukemia [16].
Oxford Gene Technology SureSeq myPanel NGS Custom AML
ASXL1 (full) NRAS (full) ETV6 (full) — —
CEBPA (full) RUNX1 (full) — — —
DNMT3A (full) TET2 (full) GATA1 (full) — —
FLT3 (full) TP53 (full) — — —
IDH1 (full) U2AF1 (full) — — —
IDH2 (full) WT1 (full) PHF6 (full) — —
KIT (full) BCOR (full) — — —
KMT2A (full) — — — —
KRAS (full) — — — —
NPM1 (full) — — — —
Total 20 genes available
The term “full” indicates all exons, and the term “hotspot” indicates hotspot exons (unmentioned here).
The term “fusion” indicates the RNA fusion partner; this genes has not been analyzed as DNA sequence, and the 
panel does not include all the RNA fusion partners.
The term “expression” indicates the analyses of quantification of gene expression at mRNA level, those genes not 
being analyzed at the DNA level.
Table 1. 
Overview of commercially available NGS panels for AML with a list of included genes [12].
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cells. In most cases, megakaryocytes are prominent and most often their size is 
increased (Figure 6) [18].
Most cases of chronic myeloid leukemia show the Philadelphia chromosome, 
which appeared after alteration of chromosome 22, produced by a reciprocal trans-
location t (9;22) q (34; 11), thus forming the BCR-ABL1 fusion gene, which became 
the main one diagnostic marker in chronic myeloid leukemia [19].
The phenotype types associated with this condition are closely correlated with 
the size of the proteins encoded by the different transcripts of the BCR-ABL1 fusion 
gene, thus noting that the most frequent rearrangements are represented by b2a2, 
followed by b3a2, following the rare alterations considered to occur in less than 2% 
of all cases of chronic myeloid leukemia. Depending on the rearrangements that have 
been undergone, theories have been issued that claim that transcript b2a2 is respon-
sible for lowering the optimal response rate, and transcript b3a2 is associated with 
better therapeutic response and longer post treatment remission [20].
NGS is now commonly used to detect mutations in the ABL1 kinase. This 
represents a mechanism of CML resistance to TKIs, being about half percent of the 
acquired resistance for CML cases where treatment failed. It has been shown that 
many unique and different kinase domain mutations are associated not only with 
imatinib resistance but also with resistance to nilotinib (Y253H, E255K, E255V, 
F359V, and F359C), dasatinib (V299L, T315A, F317L, F317I, F317V, F317V, F317V, 
and F317C), or bosutib (Y253H, V299L, and F317V) [21].
Even if these specific TKI mutations are present in less than 10% of the cases 
in which the treatment fails, the identification followed by the characterization of 
these mutations is especially important in choosing the optimal type of TKI that 
could be used even when the resistance was acquired.
Figure 6. 
Chronic myeloid leukemia staining MGG, magnification stage 1000X: (A) Patient with chronic myeloid 
leukemia, a blast accompanied by dysplastic granulocyte precursors (above the blast, there is unsegmented 
hypogranular neutrophil, and above, we see an abnormal segmented neutrophil). (B) Patient with chronic 
myeloid leukemia that displays most of granulocyte precursors (band cell, metamyelocyte, promyelocyte, a 
myelocyte with nucleo-cytoplasmatic asynchronism and below a blast cell). (C) Blast crisis in chronic myeloid 
leukemia. (D) Bone marrow aspirate of a patient with CML showing erythroid dysplasia (basophilic giant 
binucleated erythroblast) accompanied by several hypogranular granulocyte precursors.
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In the hybridization-based NGS technique, artificial oligonucleotides specially 
designed for BCR and ABL1 marker sequences are used. This specific amplifica-
tion is followed by sequencing. By in silico analyzes, with the help of software, the 
fusion junctions are identified on these sequences, whether they are determined by 
different types of chromosomal structural rearrangements such as chromosomal 
translocations, inversions, or deletions.
4. Conclusions
In the last decades, the correct evaluation of MRD has been of major importance 
for the superior management of the treatment with TKIs for patients suffering from 
CML. This process became easier and more accurate than in the case of other hema-
tological malignancies, precisely because the fundamental pathogenetic mechanism 
of this disease was studied and deciphered, which led to the use of the BCR-ABL1 
transcript as the main target of all MRD tests.
An important point in the identification and treatment of CML was the develop-
ment and adoption of NGS instruments in the clinical field to evaluate mutations 
undergone in the ABL1 kinase domain, as these mutations are responsible for 
resistance to the treatment of TKIs in any phase of the disease, either it is chronic or 
at an advanced stage. Although the Sanger sequencing method has been the most 
commonly used, the development of the NGS technique, which has a much higher 
sensitivity, enabling the detection of mutations at the subclonal level, and com-
pound mutations that are responsible for resistance to ponatinib, has led to notable 
advances in diagnosis and treatment of this disease.
In the near future, it is expected that the use of SNG will be increasingly adopted 
for patients whose first line of treatment fails but also for those who do not respond 
optimally to the additional line of treatment. However, there is still much to be done 
in this area; for example, for allogeneic transplantation, there is no NGS-generated 
data available, here Sanger is still the technique used.
The existing scientific data so far indicate that the successful therapeutic man-
agement of patients with CML is, without doubt, the close collaboration between 
biologists, technicians, and doctors, which involves primarily the use of scientific 
evidence data and innovative techniques such as those based on DNA analysis. 
Existing and ongoing networks, online databases, and ongoing development of 
methods and equipment will help to achieve these goals.
Appendices and nomenclature
FDA Food and Drug Administration
NGS next-generation sequencing
IVDs in vitro-based diagnostics
AML acute myeloid leukemia
MGG May-Grunwald-Giemsa stain
RBC red blood cells
WHO World Health Organization
CML chronic myeloid leukemia
TKIs tyrosine kinase inhibitors
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